据生物制药公司BridgeBio于11月22日宣布，美国食品药品监督管理局（FDA）批准了Attruby (acoramidis)，用于治疗患有ATTR-CM的成年人，以减少心血管死亡和心血管相关的住院治疗。新闻稿中指出，Attruby是第一个也是唯一一个药物标签上标明TTR 接近完全稳定（≥90％） 的药物。

BridgeBio Pharma的Attruby提前获批和强有力的标签，加上其有利的定价和预期的广泛使用，表明公司的市场表现前景乐观。该药物在其治疗领域对患者护理和治疗选择的潜在重大影响，现在成为投资者和行业观察者关注的焦点。

Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...

周一，在H.C. Wainwright将BridgeBio Pharma (NASDAQ:BBIO)的目标价从之前的$43.00上调至$49.00，同时维持买入评级后，该公司股价受到提振。这一调整是在BridgeBio的药物Attruby最近获得FDA批准用于治疗一种名为ATTR-CM的心脏疾病之后做出的。

2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...

11/23，FDA 批准 BridgeBio Pharma $BridgeBio Pharma(BBIO)$ 的 Attruby (acoramidis) 用于降低转甲状腺素蛋白淀粉样心肌病 (ATTR-CM) 患者的心血管死亡和心血管相关住院率，与辉瑞的 tafamidis 展开直接竞争，后者具有相同的作用机制，但批准的适应症更有限。 Attruby 是一种口服 TTR 稳定剂，FDA的批准称该 ...

The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...

Among important regulatory news last week, US drugmaker BridgeBio Pharma gained Food and Drug Administration (FDA) approval ...

The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...

The FDA has approved Attruby, a new oral treatment that helps reduce heart-related deaths and hospital visits among adults ...

See the new treatment that will break a Pfizer monopoly on a drug for heart disease.

PITTSBURGH, Nov. 26, 2024 /PRNewswire/ -- PANTHERx ® Rare, a leader in rare disease product patient access and support ...